Mycosis fungoides in the era of antitumour necrosis factor-α treatments

Br J Dermatol. 2015 Aug;173(2):590-3. doi: 10.1111/bjd.13705. Epub 2015 Jun 28.

Authors

V Nikolaou¹, E Papadavid², A Economidi², L Marinos³, E Moustou⁴, K Karampidou², T Papadaki³, A Stratigos^{2

4}, C Antoniou^{2

4}

Affiliations

¹ Lymphoma Clinic, 'A. Sygros' Hospital for Skin Diseases, 5 I. Dragoumi Str., 16121, Athens, Greece. [email protected].
² Lymphoma Clinic, 'A. Sygros' Hospital for Skin Diseases, 5 I. Dragoumi Str., 16121, Athens, Greece.
³ Hemopathology Department, 'Evagelismos' Hospital, Athens, Greece.
⁴ Psoriasis Clinic, 'A. Sygros' Hospital for Skin Diseases, 5 I. Dragoumi Str., 16121, Athens, Greece.

PMID: 25639382
DOI: 10.1111/bjd.13705

No abstract available

Publication types

Letter

MeSH terms

Adalimumab / adverse effects
Adult
Aged
Etanercept / adverse effects
Female
Humans
Immunosuppressive Agents / adverse effects*
Infliximab / adverse effects
Male
Mycosis Fungoides / chemically induced*
Mycosis Fungoides / diagnosis
Psoriasis / diagnosis
Skin Neoplasms / chemically induced*
Skin Neoplasms / diagnosis
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Immunosuppressive Agents
Tumor Necrosis Factor-alpha
Infliximab
Adalimumab
Etanercept